NCT02737332 - A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 21, 2016

Primary Completion Date

February 27, 2017

Study Completion Date

February 27, 2017

Conditions

Prostate Cancer

Interventions

DRUG

Zytiga® (Abiraterone Acetate)

Zytiga® 1,000 mg (4 x 250 mg qd) tablets plus one 5 mg prednisone tablet to be taken bid, spaced approximately 12 hours apart

DRUG

SoluMatrix™ (Abiraterone Acetate)

SoluMatrix™ 500 mg (4 x 125 mg qd) tablets plus one 4 mg methylprednisolone tablet bid, spaced approximately 12 hours apart

Trial Locations (17)

11215

Brooklyn Urology Research Group, Brooklyn

21204

Chesapeake Urology Research Associates, Towson

23462

Urology of Virginia, Virginia Beach

27612

Associated Urologist of North Carolina, Raleigh

34205

Manatee Medical Research, Bradenton

50266

The Iowa Clinic, West Des Moines

67226

Wichita Urology Group, Wichita

68130

Urology Cancer Center, Omaha

68516

Lincoln Urology, PC, Lincoln

75231

Urology Clinics of North Texas, Dallas

80113

Urology Associates, P.C., Englewood

83814

North Idaho Urology, Coeur d'Alene

90048

Tower Urology, Los Angeles

90505

Skyline Urology, Torrance

90603

Innovative Clinical Research Institute, Whittier

92404

San Bernardino Urological, San Bernardino

92653

Alliance Research, Laguna Hills

All Listed Sponsors

lead

Sun Pharmaceutical Industries Limited

INDUSTRY